{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:32Z","timestamp":1791105692717,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.nbd.2008.02.011","type":"journal-article","created":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T17:01:56Z","timestamp":1205168516000},"page":"430-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Nociceptin\/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism"],"prefix":"10.1016","volume":"30","author":[{"given":"Riccardo","family":"Viaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Sanchez-Pernaute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Trapella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Isacson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Morari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2008.02.011_bb0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0306-4522(02)00927-2","article-title":"Autoradiographic localization of (125)i[Tyr(14)] nociceptin\/orphanin FQ binding sites in macaque primate CNS","volume":"118","author":"Bridge","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2008.02.011_bb0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/sj.bjp.0704706","article-title":"[Nphe1, Arg14, Lys15]Nociceptin-NH2, a novel potent and selective antagonist of the nociceptin\/orphanin FQ receptor","volume":"136","author":"Cal\u00f2","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2008.02.011_bb0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/138945007779315605","article-title":"Nociceptin\/orphanin FQ peptide receptors: pharmacology and clinical implications","volume":"8","author":"Chiou","year":"2007","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.nbd.2008.02.011_bb0020","series-title":"The IUPHAR Compendium of Receptor Characterization and Classification","article-title":"Opioid receptors","author":"Cox","year":"2000"},{"key":"10.1016\/j.nbd.2008.02.011_bb0025","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2008.02.011_bb0030","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/BF02532380","article-title":"Rats rapidly develop tolerance to the locomotor-inhibiting effects of the novel neuropeptide orphanin FQ","volume":"21","author":"Devine","year":"1996","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.nbd.2008.02.011_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-2999(96)00707-8","article-title":"Nociceptin stimulates locomotion and exploratory behaviour in mice","volume":"317","author":"Florin","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nbd.2008.02.011_bb0040","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1046\/j.1460-9568.2003.02603.x","article-title":"Blockade of nociceptin\/orphanin FQ-NOP receptor signalling produces antidepressant-like effect: pharmacological and genetic evidences from the mouse forced swimming test","volume":"17","author":"Gavioli","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.nbd.2008.02.011_bb0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson's disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.nbd.2008.02.011_bb0050","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1073\/pnas.090514397","article-title":"A synthetic agonist at the orphanin FQ\/nociceptin receptor ORL1: anxiolytic profile in the rat","volume":"97","author":"Jenck","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2008.02.011_bb0055","doi-asserted-by":"crossref","first-page":"9553","DOI":"10.1523\/JNEUROSCI.1558-04.2004","article-title":"Mapping dopamine function in primates using pharmacologic magnetic resonance imaging","volume":"24","author":"Jenkins","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2008.02.011_bb0060","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.brainres.2004.09.046","article-title":"Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice","volume":"1030","author":"Kato","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2008.02.011_bb0065","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1021\/jm990517p","article-title":"Discovery of the first potent and selective small molecule opioid receptor-like (ORL1) antagonist: 1-[3R, 4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H benzimidazol-2-one (J-113397)","volume":"42","author":"Kawamoto","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.nbd.2008.02.011_bb0070","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/jpet.106.106120","article-title":"Effects of intrathecally administered nociceptin\/orphanin FQ in monkeys: behavioral and mass spectrometric studies","volume":"318","author":"Ko","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2008.02.011_bb0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.bjp.0705906","article-title":"The NOP (ORL1) receptor antagonist Compound B stimulates mesolimbic dopamine release and is rewarding in mice by a non-NOP-receptor-mediated mechanism","volume":"143","author":"Koizumi","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2008.02.011_bb0080","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/sj.bjp.0705583","article-title":"Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors","volume":"141","author":"Kuzmin","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2008.02.011_bb0085","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1523\/JNEUROSCI.0987-04.2004","article-title":"Blockade of nociceptin\/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior","volume":"24","author":"Marti","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2008.02.011_bb0090","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1471-4159.2004.02843.x","article-title":"Blockade of nociceptin\/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release","volume":"91","author":"Marti","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2008.02.011_bb0095","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1523\/JNEUROSCI.2546-05.2005","article-title":"Blockade of nociceptin\/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease","volume":"95","author":"Marti","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2008.02.011_bb0100","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1523\/JNEUROSCI.4346-06.2007","article-title":"The nociceptin\/orphanin FQ receptor antagonist J-113397 and L-Dopa additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway","volume":"27","author":"Marti","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2008.02.011_bb0105","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/mds.21010","article-title":"Behavioral models of Parkinson's disease in rodents: a new look at an old problem","volume":"21","author":"Meredith","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2008.02.011_bb0110","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/377532a0","article-title":"Isolation and structure of the endogenus agonist of opioid receptor-like ORL1 receptor","volume":"377","author":"Meunier","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2008.02.011_bb0115","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0891-0618(01)00135-1","article-title":"Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain","volume":"22","author":"Neal","year":"2001","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.nbd.2008.02.011_bb0120","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/emboj\/16.8.1858","article-title":"Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin\/orphanin FQ receptor","volume":"16","author":"Nishi","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.nbd.2008.02.011_bb0125","doi-asserted-by":"crossref","first-page":"PL133","DOI":"10.1016\/0024-3205(94)00749-7","article-title":"NE-100, a novel sigma receptor ligand: effect on phencyclidine-induced behaviors in rats, dogs and monkeys","volume":"55","author":"Okuyama","year":"1994","journal-title":"Life Sci."},{"key":"10.1016\/j.nbd.2008.02.011_bb0130","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1523\/JNEUROSCI.1069-07.2007","article-title":"Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of basal ganglia injury","volume":"27","author":"Petzinger","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2008.02.011_bb0135","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.270.5237.792","article-title":"Orphanin FQ: a neuropeptide that activates an opioid-like G protein-coupled receptor","volume":"270","author":"Reinscheid","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.nbd.2008.02.011_bb0140","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/jpet.106.116780","article-title":"Pharmacological characterization of the nociceptin\/orphanin FQ receptor antagonist SB-612111 [(\u2212)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H benzocyclohepten-5-ol]: in vivo studies","volume":"32","author":"Rizzi","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2008.02.011_bb0145","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1385-299X(97)00034-2","article-title":"An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism","volume":"2","author":"Rozas","year":"1997","journal-title":"Brain Res. Protoc."},{"key":"10.1016\/j.nbd.2008.02.011_bb0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00213-003-1643-3","article-title":"Central administration of nociceptin\/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice","volume":"172","author":"Sakoori","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nbd.2008.02.011_bb0155","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: its ups and downs","volume":"102","author":"Sanberg","year":"1988","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.nbd.2008.02.011_bb0160","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.nbd.2007.04.016","article-title":"In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias","volume":"27","author":"Sanchez-Pernaute","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2008.02.011_bb0165","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1001958023096","article-title":"MPTP susceptibility in the mouse: behavioural, neurochemical and histological analysis of gender and strain differences","volume":"30","author":"Sedelis","year":"2000","journal-title":"Behav. Genet."},{"key":"10.1016\/j.nbd.2008.02.011_bb0170","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0166-4328(01)00309-6","article-title":"Behavioral phenotyping of the MPTP mouse model of Parkinson's disease","volume":"125","author":"Sedelis","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.nbd.2008.02.011_bb0175","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00213-005-0041-4","article-title":"Characterization of the nociceptin receptor (ORL-1) agonist, Ro64-6198, in tests of anxiety across multiple species","volume":"182","author":"Varty","year":"2005","journal-title":"Psycopharmacology (Berl.)"},{"key":"10.1016\/j.nbd.2008.02.011_bb0180","first-page":"5","article-title":"Nociceptin\/orphanin FQ receptors modulate locomotion and motor cortex excitability in adult rats","volume":"188","author":"Viaro","year":"2006","journal-title":"Acta Physiol."},{"key":"10.1016\/j.nbd.2008.02.011_bb0185","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11011-007-9080-3","article-title":"Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease","volume":"23","author":"Watanabe","year":"2008","journal-title":"Metab. Brain Dis."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996108000454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996108000454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T05:03:15Z","timestamp":1760850195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996108000454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0969996108000454"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2008.02.011","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nociceptin\/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2008.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}